October 22, 2017
WASHINGTON — Results of a virtual trial showed that transplantation with hepatitis C-positive livers with preemptive direct-active antiviral therapy may be a viable option for improving patient survival on the liver transplant waitlist, according to an expert at The Liver Meeting 2017.
“The fact is that donor liver availability continues to be limiting factor in increasing the number of liver transplants. Therefore, it becomes very important that we utilize all organs for a maximum potential,” Jagpreet Chhatwal, PhD, from the Massachusetts General Hospital and Harvard Medical School, said in his presentation. “However, under current guidelines, hep C-positive livers are not transplanted into hep C-negative recipients because of adverse post-transplant outcomes previously demonstrated in the interferon-based therapy [era]. But several things have changed in the last few years that prompt us to revisit this question.”